| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/05/2012 | US20120004316 Treating impulse control disorders with catechol-o-methyl-transferase inhibitors |
| 01/05/2012 | US20120004315 Selective Estrogen Receptor Modulator |
| 01/05/2012 | US20120004313 Crystalline form vi of agomelatine, preparation method and application thereof |
| 01/05/2012 | US20120004311 Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic b-cell lymphoma/leukemia-2 (bcl-2) |
| 01/05/2012 | US20120004310 Non-peptide bdnf neurotrophin mimetics |
| 01/05/2012 | US20120004309 Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof |
| 01/05/2012 | US20120004307 Oral treatment of digital ischemic lesions |
| 01/05/2012 | US20120004306 External preparation containing analgesic/anti-inflammatory agent |
| 01/05/2012 | US20120004300 Methods for treating bipolar disorder |
| 01/05/2012 | US20120004277 Vector(s) containing an inducible gene encoding a cdk4/cdk6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle |
| 01/05/2012 | US20120004275 Sceletium extract and uses thereof |
| 01/05/2012 | US20120004273 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders |
| 01/05/2012 | US20120004270 Selective Androgen Receptor Modulators |
| 01/05/2012 | US20120004267 Apoptosis signal-regulating kinase inhibitors |
| 01/05/2012 | US20120004266 Dopamine-beta-hydroxylase genetic polymorphism and migraine |
| 01/05/2012 | US20120004263 Compounds for the treatment of pathologies associated with aging and degenerative disorders |
| 01/05/2012 | US20120004257 Novel compounds |
| 01/05/2012 | US20120004254 G protein-coupled receptor antagonist and its use for preventing and treating alzheimer's disease |
| 01/05/2012 | US20120004253 Novel Fused Pyrrolocarbazoles |
| 01/05/2012 | US20120004252 New ccr2 receptor antagonists and uses thereof |
| 01/05/2012 | US20120004251 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy |
| 01/05/2012 | US20120004246 Purinyl derivatives and their use as potassium channel modulators |
| 01/05/2012 | US20120004244 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors |
| 01/05/2012 | US20120004243 Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors |
| 01/05/2012 | US20120004242 Oligomer-Diarylpiperazine Conjugates |
| 01/05/2012 | US20120004241 Succinate salt of (2r)-methyl-1-piperazine |
| 01/05/2012 | US20120004239 Process for Preparing Quinoxaline Derivatives |
| 01/05/2012 | US20120004238 L-methylfolate treatment for psychiatric or neurologic disorders |
| 01/05/2012 | US20120004236 Substituted triazolo-pyridazine derivatives |
| 01/05/2012 | US20120004232 2-amino-bicyclo(3.1.0) hexane-2, 6-dicarboxylic ester derivative |
| 01/05/2012 | US20120004231 Substituted Pyridazine Derivatives |
| 01/05/2012 | US20120004230 Imidazole derivatives |
| 01/05/2012 | US20120004228 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors |
| 01/05/2012 | US20120004226 Modulators of Muscarinic Receptors |
| 01/05/2012 | US20120004225 Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use |
| 01/05/2012 | US20120004220 Selective androgen receptor modulators (sarms) and uses thereof |
| 01/05/2012 | US20120004217 Therapeutic agents useful for treating pain |
| 01/05/2012 | US20120004216 Modulators of atp-binding cassette transporters |
| 01/05/2012 | US20120004215 N-oxides of diazabicyclononyl pyrimidine derivatives and their medical use |
| 01/05/2012 | US20120004214 N-oxides of 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives useful as nicotinic acetylcholine receptor ligands |
| 01/05/2012 | US20120004211 1,2,4-triazole derivatives as sigma receptor inhibitors |
| 01/05/2012 | US20120004208 Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors |
| 01/05/2012 | US20120004207 Therapeutic uses of derivatives of piperidinyl-and piperidinyl-alkyl carbamates |
| 01/05/2012 | US20120004206 Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| 01/05/2012 | US20120004201 Phosphodiestarase inhibitors |
| 01/05/2012 | US20120004200 Topical pharmaceutical composition containing a water-sensitive active principle |
| 01/05/2012 | US20120004193 Process for production of orally ingestible composition containing arabinofuranosyl vitexin, and use of the composition |
| 01/05/2012 | US20120004192 Use of lactulose in the treatment of autism |
| 01/05/2012 | US20120004184 Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
| 01/05/2012 | US20120004180 Method of producing a novel opioid peptide |
| 01/05/2012 | US20120004178 Biglycan mutants and related therapeutics and methods of use |
| 01/05/2012 | US20120004175 Inhibitors of nf-kb activity |
| 01/05/2012 | US20120004174 Gh secretagogues and uses thereof |
| 01/05/2012 | US20120004170 Formulation Comprising Bioactive Agents And Method Of Using Same |
| 01/05/2012 | US20120003341 Nutraceutical Product Containing Anatabine And Yerba Maté |
| 01/05/2012 | US20120003330 Benzoquinolone inhibitors of vmat2 |
| 01/05/2012 | US20120003316 Transmucosal delivery system |
| 01/05/2012 | US20120003312 Multilayer Minitablets with Different Release Rates |
| 01/05/2012 | US20120003310 Delayed release rasagiline formulation |
| 01/05/2012 | US20120003307 Levetiracetam controlled release composition |
| 01/05/2012 | US20120003290 Method for reducing pain |
| 01/05/2012 | US20120003282 Pharmaceutical compositions of dextran polymer derivatives |
| 01/05/2012 | US20120003274 Oral sustained release antidepressant formulation |
| 01/05/2012 | US20120003252 Isoforms of human somatostatin receptor type 5 produced by alternative processing and oligo-nucleotide pairs for detection thereof by pcr |
| 01/05/2012 | US20120003243 Yeast ectopically expressing abnormally processed proteins and uses therefor |
| 01/05/2012 | US20120003235 Anti-lymphotoxin antibodies |
| 01/05/2012 | US20120003228 Methods for predicting autoimmune disease risk |
| 01/05/2012 | US20120003200 Biologically active food supplement |
| 01/05/2012 | US20120003190 Lateral ventricle cell compositions and use for treating neural degenerative diseases |
| 01/05/2012 | US20120003186 Method for dedifferentiating adipose tissue stromal cells |
| 01/05/2012 | US20120003183 Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as dhodh inhibitors |
| 01/05/2012 | US20120003182 Genetic severity markers in multiple sclerosis |
| 01/05/2012 | US20120003180 Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function |
| 01/05/2012 | US20120003175 Therapeutic uses of mastic gum fractions |
| 01/05/2012 | US20120003153 Novel indolyl-oxadiazolyl-diazabicyclononane derivatives and their medical and diagnostical use |
| 01/05/2012 | US20120000998 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 01/05/2012 | DE102010026090A1 Preparing a matrix for a sublingual dosage form, preferably a tablet, comprises preparing a mixture of gum arabic and active ingredients, and extruding the obtained mixture |
| 01/05/2012 | CA2807303A1 Inhibition of inflammation by simultaneous blockade of multiple prostanoid receptors |
| 01/05/2012 | CA2805024A1 Polypeptides and uses thereof as a drug for treatment of multiples sclerosis, rheumatoid arthritis and other autoimmune disorders |
| 01/05/2012 | CA2804174A1 Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
| 01/05/2012 | CA2804154A1 Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function |
| 01/05/2012 | CA2804016A1 L-methylfolate treatment for psychiatric or neurologic disorders |
| 01/05/2012 | CA2804001A1 Methods for treating post traumatic stress disorder |
| 01/05/2012 | CA2803668A1 Treatment of cognitive disorders |
| 01/05/2012 | CA2803577A1 2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors |
| 01/05/2012 | CA2802606A1 Formulations and delivery |
| 01/05/2012 | CA2802380A1 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatment of alzheimer's disease and other forms of dementia |
| 01/05/2012 | CA2801243A1 Methods of treating restless legs syndrome |
| 01/05/2012 | CA2801241A1 Methods for treating bipolar disorder |
| 01/04/2012 | EP2402756A2 Agonist anti-trkC antibodies and methods using same |
| 01/04/2012 | EP2402362A2 Crystalline forms of smilagenin |
| 01/04/2012 | EP2402349A1 Tricyclic pyrazolopyrimidine derivative |
| 01/04/2012 | EP2402326A1 Crystals of hydrochloride salts of a Phenylalanine Derivative, Production Method Thereof and Use Thereof as alpha4 integrin Inhibitors |
| 01/04/2012 | EP2402322A1 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist |
| 01/04/2012 | EP2402311A1 Modafinil polymorphic form VI |
| 01/04/2012 | EP2402310A1 CCR9 inhibitors and methods of use thereof |
| 01/04/2012 | EP2402309A1 CCR9 inhibitors and methods of use thereof |
| 01/04/2012 | EP2402037A1 Controlled release of phenolic opioids |
| 01/04/2012 | EP2402002A1 Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| 01/04/2012 | EP2401277A1 Salt of tetrahydrotriazolopyridine derivative and crystal thereof |